Genetic Testing Lawsuit: PGT-A Class Actions, Accuracy, and Courts

A growing PGT-A class action lawsuit docket now spans at least nine federal cases, with IVF patients accusing genetic testing companies of overstating the accuracy of preimplantation genetic testing for aneuploidy and causing families to discard embryos that may have been healthy. The first wave was filed in October 2024, and by early 2025 nearly 700 patients had joined. New defendants have been added as recently as March 2026.1Time. IVF PGT-A Test Lawsuit

Which Companies Have Been Sued

The complaints target laboratories that sell PGT-A screening and, in one case, a fertility clinic network that marketed it. Filings to date:

The consortium of firms leading the litigation — Constable Law, Berger Montague, and Justice Law Collaborative — has said it expects to file suits against additional testing companies.9Justice Law Collaborative. Press Release: Class Action Lawsuits Filed Against Genetic Testing Companies

What the Lawsuits Allege

The complaints share a common theory: consumer fraud, breach of warranty, and related claims tied to how PGT-A was marketed. Plaintiffs say the companies sold the test as an accurate, proven way to raise IVF success rates, cut miscarriage risk, and shorten the time to pregnancy. Some companies advertised accuracy of 97% to 99%.10ClassAction.org. Weinberg et al v. CooperGenomics Inc. et al

According to the complaints, those claims are not supported by randomized, non-commercially funded trials showing improved implantation, pregnancy, or live birth rates. Plaintiffs also point to major insurers, including United Healthcare and Aetna, treating PGT-A as “not medically necessary” or “experimental,” and allege the companies knew about significant false-positive rates without disclosing them. The complaints add that the biopsy and freeze-thaw process required for PGT-A can itself damage embryos.11ClassAction.org. PGT-A IVF Genetic Testing Lawsuit

Plaintiffs are seeking reimbursement of out-of-pocket testing costs, statutory damages, and court orders forcing companies to disclose the test’s limitations going forward.3Berger Montague. PGT-A Lawsuit

Why the Accuracy Is Disputed

PGT-A works by removing a few cells from an embryo’s outer layer and screening them for chromosomal abnormalities. Embryos labeled “aneuploid” are usually not transferred and are often discarded; those labeled “euploid” are prioritized. The test is generally not covered by insurance and costs patients thousands of dollars out of pocket.

The core scientific question is whether a handful of cells accurately represents the whole embryo. A 2024 study of 23 embryos initially classified as aneuploid found that in nearly 48% of cases the initial result did not reflect the embryo’s true chromosomal status; 11 of the 23 showed no evidence of the aneuploidy PGT-A had detected.12National Center for Biotechnology Information. Concordance Analysis of PGT-A Blastocysts A 2025 meta-analysis in PLOS One put the misdiagnosis rate for aneuploid-screened embryos at 10.6%, rising to 21.7% for embryos categorized as mosaic.13PLOS One. Diagnostic Accuracy of PGT-A: Systematic Review and Meta-Analysis

Medical societies have taken cautious positions. In a 2024 committee opinion, the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology concluded that “the value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated,” and that “the value of PGT-A to lower the risk of clinical miscarriage is also unclear.”14ASRM. The Use of Preimplantation Genetic Testing for Aneuploidy: A Committee Opinion The American College of Obstetricians and Gynecologists said “the best use of [PGT-A] remains to be determined” and warned that false positives and false negatives are possible with any testing method.15ACOG. Preimplantation Genetic Testing

What the Courts Have Done So Far

Two early rulings have already reshaped the landscape, and neither favored plaintiffs.

In the Ovation Fertility case, U.S. District Judge Noreika dismissed the complaint on September 3, 2025, finding that plaintiffs had not established Article III standing. The court held the complaint did not allege that PGT-A had actually failed for the named plaintiffs or that their individual results were defective. Dismissal was without prejudice, but no amended complaint was filed, and the case was terminated on October 24, 2025.4U.S. District Court for the District of Delaware. Klosowski v. FPG Labs, Memorandum Opinion16PACER Monitor. Klosowski et al v. FPG Labs, LLC et al

In the Igenomix case, Judge William P. Dimitrouleas granted the defendants’ motion to compel arbitration in February 2026 and administratively closed the case. Vitrolife AB, the Swedish parent company, was dismissed for lack of personal jurisdiction.5PACER Monitor. M. et al v. Vitrolife Inc. et al

Motions to dismiss have been filed by CooperSurgical, Natera, RGI, and Ovation Fertility, and Progenesis filed a motion for judgment on the pleadings.1Time. IVF PGT-A Test Lawsuit Rulings on the motions in the CooperGenomics, Natera, RGI, and Progenesis cases have not been publicly reported as of mid-2026. The CCRM, Luminary Genetics, and Genomic Prediction cases are at earlier stages.

The Patient Experiences Behind the Cases

The named plaintiffs describe decisions they cannot undo. Shannon Petersen was told all five of her embryos were “abnormal,” with one flagged for a “serious chromosomal abnormality.” She later became pregnant with that embryo and delivered a healthy baby boy in November 2024. Alexandra Zuk was told her embryos were not viable and discarded them; she is now a plaintiff. Jaime Magnetico-Walsh’s clinic had retained three “mosaic” embryos she was told were abnormal, and two of those retested as normal. Katie Herrero discarded 10 embryos labeled aneuploid in 2019 and later learned one was a “complex mosaic” that may have been viable.1Time. IVF PGT-A Test Lawsuit Maureen Ewing, a plaintiff in the Genomic Prediction case, said she destroyed embryos based on test results labeling them abnormal and described the experience as “crushing.”17The Independent. New Jersey Genetic Testing IVF Embryos Lawsuit

How the Companies Have Responded

A Natera spokesperson called the litigation “baseless,” said PGT-A is “an important screening tool,” and stood by the accuracy the company reports as supported by peer-reviewed studies. Natera also said doctors, not the testing company, decide how the test is used in patient care.1Time. IVF PGT-A Test Lawsuit In March 2026, Natera added that “the plaintiffs do not allege that the accuracy of Natera’s PGT-A test is in question.”18Bay News 9. Lawsuit IVF Test PGT-A Misleading

Genomic Prediction said it stands “by the integrity of our work” and remains “committed to the highest standards of scientific rigor, transparency, and patient care,” and declined further comment during active litigation.17The Independent. New Jersey Genetic Testing IVF Embryos Lawsuit A representative for Igenomix’s parent, Vitrolife Group, said its legal counsel was reviewing the case. RGI and Ovation Fertility declined to comment; CooperSurgical and Progenesis did not respond to press inquiries.1Time. IVF PGT-A Test Lawsuit

Don’t Confuse This With the Natera Prenatal Settlement

Natera is also involved in separate litigation over its prenatal screening products, which is not the same as the PGT-A cases. A proposed $8.25 million class action settlement in In re Natera Prenatal Testing Litigation, No. 4:22-cv-00985 (N.D. Cal.), received preliminary approval from Judge Jon S. Tigar in August 2025.19Bloomberg Law. Natera Gets First Nod for $8.25 Million Prenatal Test Settlement That case covers the Panorama and Vasistera noninvasive prenatal screening tests taken during pregnancy, not the PGT-A testing performed on IVF embryos. Eligible class members are people who paid out of pocket for those prenatal tests. The claim filing deadline is July 24, 2026, and the final approval hearing is scheduled for August 20, 2026.20Natera NIPT Settlement. In re Natera Prenatal Testing Litigation Settlement If you paid for PGT-A during IVF, that settlement does not apply to you.

If You Had PGT-A Testing

The PGT-A cases remain in early or contested stages, and two of them have already been knocked out on standing and arbitration grounds. Patients who paid for PGT-A and believe their results led them to discard embryos are the population the plaintiffs’ firms are recruiting; the consortium behind the litigation has said more cases against additional companies are likely to follow.9Justice Law Collaborative. Press Release: Class Action Lawsuits Filed Against Genetic Testing Companies No class has yet been certified in the pending U.S. cases, and no settlement has been reached.